These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. Ramos-Cebrián M, Torregrosa JV, Gutiérrez-Dalmau A, Oppenheimer F, Campistol JM. Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154 [Abstract] [Full Text] [Related]
31. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. Cofan F, Cofan M, Campos B, Guerra R, Campistol JM, Oppenheimer F. Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540 [Abstract] [Full Text] [Related]
32. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression. Hoitsma AJ, Hilbrands LB. Clin Transplant; 2006 Nov; 20(5):659-64. PubMed ID: 16968494 [Abstract] [Full Text] [Related]
38. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. Sharma A, Shekhar C, Heer M, Minz M. Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996 [Abstract] [Full Text] [Related]
39. The influence of calcineurin inhibitors on pulse wave velocity in renal transplant recipients. Strózecki P, Adamowicz A, Włodarczyk Z, Manitius J. Ren Fail; 2007 Sep; 29(6):679-84. PubMed ID: 17763162 [Abstract] [Full Text] [Related]